Unique ID issued by UMIN | UMIN000037335 |
---|---|
Receipt number | R000042561 |
Scientific Title | Efficacy and safety of Movicol in combination with or after switching from the existing therapy in patients with chronic constipation (Retrospective observation research) |
Date of disclosure of the study information | 2019/07/11 |
Last modified on | 2019/12/23 17:10:13 |
Efficacy and safety of Movicol in combination with or after switching from the existing therapy in patients with chronic constipation(Retrospective observation research)
Efficacy and safety of Movicol in combination with or after switching from the existing therapy in patients with chronic constipation(Retrospective observation research)
Efficacy and safety of Movicol in combination with or after switching from the existing therapy in patients with chronic constipation (Retrospective observation research)
Efficacy and safety of Movicol in combination with or after switching from the existing therapy in patients with chronic constipation (Retrospective observation research)
Japan |
Chronic constipation
Hepato-biliary-pancreatic medicine |
Others
NO
To examine efficacy and safety of Movicol in combination with or after switching from the existing therapy (magnesium oxide, etc.) in patients with chronic constipation with inadequate response to the existing therapy.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
Comparison of CSS total score between baseline and at Week 4 of administration
JPAC-QOL score
CSS total score (of each evaluation time point from baseline to Week 8)
CSS sub score (at each evaluation time point from baseline to Week 8)
Bristol Stool Form Scale
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) Patients diagnosed with chronic constipation and assessed as inadequate responders to the existing therapy (magnesium oxide, etc.)
2) Patients with 20 years or older at baseline
3) Patients receiving Movicol during the investigation period
4) Patients receiving the existing therapy (magnesium oxide, etc.) from more than 2 weeks before administration of Movicol
1) Patients who are suspected constipation due to organic disease
2) Patients with a history of hypersensitivity to any ingredients of Movicol
3) Patients who are confirmed or suspected intestinal obstruction, intestinal perforation, or severe inflammatory bowel disease (ulcerative colitis, Crohn's disease, toxic megacolon, etc.)
40
1st name | Takafumi |
Middle name | |
Last name | Maeda |
TSUJINAKA HOSPITAL KASHIWANOHA
Coloprocrology
277-0871
148 Block 6 of the Kashiwanoha Campus,178-2,Wakashiba, Kashiwa, Chiba
04-7137-3737
takafumisachiyo@yahoo.co.jp
1st name | Takafumi |
Middle name | |
Last name | Maeda |
TSUJINAKA HOSPITAL KASHIWANOHA
Coloprocrology
277-0871
148 Block 6 of the Kashiwanoha Campus,178-2,Wakashiba, Kashiwa, Chiba
04-7137-3737
takafumisachiyo@yahoo.co.jp
TSUJINAKA HOSPITAL KASHIWANOHA
EA Pharma Co., LTD
Profit organization
Joint Ethical Review Board
1-14, Minamikubo, Kochi City, Kochi Prefecture
042-648-5551
godou-irb@epsogo.co.jp
NO
医療法人社団康喜会 辻仲病院柏の葉
2019 | Year | 07 | Month | 11 | Day |
Unpublished
67
Completed
2019 | Year | 06 | Month | 06 | Day |
2019 | Year | 06 | Month | 24 | Day |
2019 | Year | 06 | Month | 06 | Day |
2019 | Year | 07 | Month | 11 | Day |
2019 | Year | 07 | Month | 31 | Day |
2019 | Year | 08 | Month | 20 | Day |
Comparison of the total constipation scoring system (CSS) score at baseline and Week 4
2019 | Year | 07 | Month | 11 | Day |
2019 | Year | 12 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042561